FDMT

4D Molecular Therapeutics (FDMT)

About 4D Molecular Therapeutics (FDMT)

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Details

Daily high
$9.19
Daily low
$8.85
Price at open
$9.03
52 Week High
$36.25
52 Week Low
$8.53
Market cap
462.0M
Dividend yield
0.00%
Volume
332,331
Avg. volume
1.3M
P/E ratio
-3.25

4D Molecular Therapeutics News

Details

Daily high
$9.19
Daily low
$8.85
Price at open
$9.03
52 Week High
$36.25
52 Week Low
$8.53
Market cap
462.0M
Dividend yield
0.00%
Volume
332,331
Avg. volume
1.3M
P/E ratio
-3.25